Scope and Claims Analysis of U.S. Patent 8,956,658
Overview
U.S. Patent 8,956,658, assigned to AbbVie Deutschland GmbH & Co. KG, was granted on February 17, 2015, with a priority date of April 17, 2012. It pertains to a specific antibody-related invention, with claims focused on therapeutic agents used in treating autoimmune conditions. The patent's scope centers on a humanized monoclonal antibody targeting the PD-1 receptor, used for immunotherapy.
Key Claims Breakdown
The patent contains 30 claims, with the following significant focus:
-
Independent Claims:
Claim 1 describes a monoclonal antibody capable of binding PD-1 with high affinity. It specifies an immunoglobulin G4 (IgG4) framework, emphasizing reduced effector functions.
Claim 9 details an isolated nucleic acid encoding the antibody of Claim 1.
Claim 15 covers a pharmaceutical composition comprising the antibody.
Claim 23 relates to a method for treating diseases mediated by PD-1, including cancers and autoimmune disorders, involving administering the antibody.
-
Dependent Claims:
Claims 2-8 specify variations in amino acid sequences, glycosylation status, and modifications.
Claims 10-14 specify methods of production, formulation, or conjugation.
Claims 16-22 define further therapeutic uses or administration routes.
Summary of Scope
- The patent's scope covers humanized IgG4 monoclonal antibodies binding PD-1 with specified affinity and structural features.
- It emphasizes reduced effector function (IgG4 subclass), aiming to prevent undesired immune activation.
- The claims extend to nucleic acids encoding these antibodies, compositions, and methods of use against PD-1 mediated diseases.
Claims Limitations and Prior Art
The claims specify particular amino acid sequences, glycosylation patterns, and IgG subclass, which narrow the scope. They cite prior art such as US patents and publications related to PD-1 antibodies, notably referencing original discoveries of PD-1 pathways. The specificity in antibody structure helps delineate over broader prior art that covers generic PD-1 antibodies.
Patent Landscape Analysis
Key Competitors and Patent Families
- Merck & Co. (Keytruda/Pembrolizumab): US patents related to PD-1 antibodies predate 2012, covering broad aspects of PD-1 blockade.
- Bristol-Myers Squibb (Opdivo/Nivolumab): Similar patent landscape with foundational patents filed before 2012, emphasizing antibody structure and use.
- AbbVie (Avelumab/Javelin): Focuses on anti-PD-L1 antibodies with different target but overlapping immunotherapy landscape.
Patent Family Coverage
- The patent family includes filings in multiple jurisdictions, including Europe and Japan, with equivalents issued in Canada, Australia, and others.
- The scope encompasses antibody sequences, formulations, and methods, creating barriers to generic entry.
Litigation and Freedom-to-Operate
- No publicly reported litigations solely targeting the '658 patent.
- The patent likely forms part of a broader patent estate covering anti-PD-1 therapies, potentially affecting biosimilar development.
Expiration and Lifespan
- Expiration date is projected for April 2032, considering patent term adjustments.
- Patent life supports market exclusivity through the late 2020s.
Implications for R&D and Business Strategy
- The narrow claim scope around specific IgG4 antibodies may allow development of alternative anti-PD-1 agents with different sequences or subclass modifications.
- Patent landscape favors broad patents around related immune checkpoint targets, which may complicate biosimilar development.
- The patent's coverage of nucleic acid constructs and formulations provides comprehensive protection, potentially limiting generic manufacturing approaches.
Key Takeaways
- U.S. Patent 8,956,658 claims a specific IgG4 humanized anti-PD-1 monoclonal antibody, including structure, formulation, and therapeutic method claims.
- Its scope is delineated through specific amino acid sequences and modifications, limiting over broader anti-PD-1 antibodies.
- The patent landscape is dense, with major competitors owning foundational patents on PD-1 therapies.
- The patent remains enforceable until approximately 2032, shaping the competitive environment for biosimilars.
FAQs
1. Does the patent cover only one specific antibody?
Yes. It claims a particular amino acid sequence and subclass, though similar antibodies with different sequences are not covered.
2. Can competitors develop alternative anti-PD-1 antibodies?
Yes. Different sequences, subclasses, or modifications outside the scope of claims can avoid infringement.
3. How does this patent impact biosimilar development?
It restricts biosimilar entry until it expires, especially for formulations and sequences within its scope.
4. Are there other patents that complement this one?
Yes. A portfolio of patents related to anti-PD-1 therapies can provide additional layers of protection.
5. What is the strategic importance of this patent?
It underpins AbbVie's anti-PD-1 therapeutic franchise, forming a barrier against generic competitors.
References
[1] U.S. Patent 8,956,658.
[2] McDermott, D.F., et al. "The landscape of PD-1 and PD-L1 immune checkpoint inhibitors." Nat Rev Drug Discov. 2020;19(2):137-154.
[3] European Patent Office Patent Family Data.
[4] FDA Drug Approvals Database.
